Skip to main content
PolicySpeak
← All files
DG

Dedalus Group

Company · Italy · EU Transparency Register 810154494287-18

9
positions filed
in the 326 files tracked
8
legislative files
of 326 tracked
6
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 925 companies & groups on this site, they rank #57 by legislative files engaged — a count of participation, not a measure of influence.

0.6
declared lobbying FTE
self-declared
€50K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2024
in the register since

Declares membership of

  • Trade organization COCIR (www.cocir.org),
  • HIMSS (https://www.himss.org/),
  • IHE-Europe (https://www.ihe-europe.net/),
  • openEHR (https://openehr.org/)

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).

Register category
Companies & groups
Registered as
Dedalus S.p.A.
Head office
Milano, Italy

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track Dedalus in PolicySpeak: request access →

Work at Dedalus Group? so we know who speaks for it.

Follow the files Dedalus Group engages with

One email on Tuesdays when a new position is filed on these 8 files, from Dedalus Group or from anyone else on them. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

Dedalus Group filed 9 positions between 15 Apr 2025 and 3 Aug 2026, across 8 of the 326 legislative files tracked here, attaching a full position paper 6 times.

2025 · 3 filed2026 · 6 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 3 Aug 2026PDFsource

MDR/IVDR Targeted Revision (COM(2025) 1023): Dedalus, a European healthcare software group (7,000+ employees, standalone software medical devices used by hospitals across the EU), welcomes the Commission proposal as a strong basis for restoring proportionality, predictability and international competitiveness while maintaining patient safety.

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025PDFsource

Dedalus is a well-established European-based medical software manufacturer regulated under MDR and IVDR. Our portfolio spans primary care, hospital systems, diagnostics, emergency care, and population health management.

European Open Digital Ecosystemsfiled 29 Jan 2026source

Health IT applications have mission-critical components that directly support clinical decision-making, patient identification, medication management, diagnostics, care coordination, and continuity of operations.

Amending the NIS 2 Directive as regards simplification measures and alignment with the Cybersecurity Act 2filed 11 May 2026PDFsource

Dedalus welcomes the opportunity to provide input to the Cybersecurity Act 2 and NIS2 Simplification Measures proposals. As a European leader in Software as a Medical Device (SaMD) and AIenabled medical devices (MDAI), serving large hospital networks across the Union, Dedalus strongly supports the objective of creating a predictable, innovationfriendly, and clinically safe digital regulatory environment.

EU quantum Actfiled 11 Dec 2025PDFsource

1. Quantum-safe protection of sensitive health data. The Act should explicitly support the transition to post-quantum cryptography (PQC) for electronic health records, communications, digital signatures, and authentication systems, in coordination with ENISA, ETSI, EuroQCI and national cybersecurity authorities. 2. Quantum-ready interoperability and standards.

Technical description of important and critical products with digital elementsfiled 15 Apr 2025PDFsource

Dedalus S.p.A., as a group developing and distributing medical software within the European Union, would like to express our sincere appreciation for the European Commission's efforts in advancing cybersecurity through the Cyber Resilience Act (CRA). We welcome the orientation, clarity, and strategic foresight demonstrated by the CRA.

European Health Data Space Board operationsfiled 2 Jan 2026source

Dedalus Group welcomes the publication of the draft implementing regulation on the European Health Data Space (EHDS) Board and appreciates the effort to establish a governance framework that promotes coordination and transparency. In this context, we would like to offer some recommendations aimed at strengthening inclusiveness, clarity, and moving to effective implementations.

Review of the European interoperability frameworkfiled 14 Jul 2026source

The European Interoperability Framework should continue to play a central role in enabling the effective functioning of cross-border digital public services. Its core principlesmultilayer interoperability, reuse, openness and interoperability by designremain valid and should be further strengthened.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Turns up on the same files

Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.

Showing 5 of 99.

Is this your organization?

Everything on this page comes from Dedalus Group’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.